Malkevitch Nina V, Robert-Guroff Marjorie
Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 5065, USA.
Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S105-17. doi: 10.1586/14760584.3.4.s105.
A key challenge to HIV vaccine development is the integration of HIV proviral DNA into the host genome upon infection. Therefore, an optimal vaccine should block infection within hours of viral exposure, providing 'sterilizing immunity' at mucosal sites and in blood via potent, broadly reactive antibody to the HIV envelope glycoprotein. This is difficult due to the envelope's conformational complexity and sequence diversity. Antibodies that do not completely prevent infection nevertheless could reduce the viral infectious burden, allowing strong cellular immunity to control viremia, delay disease progression and prevent viral transmission, while also providing help for T- and B-cell responses. Rapidly responsive, potent, persistent immunity might best be achieved using prime-boost strategies incorporating a replicating vector and an optimally designed envelope subunit.
艾滋病毒疫苗研发面临的一个关键挑战是,感染时艾滋病毒前病毒DNA会整合到宿主基因组中。因此,一种理想的疫苗应在病毒暴露数小时内阻断感染,通过针对艾滋病毒包膜糖蛋白的强效、广泛反应性抗体,在黏膜部位和血液中提供“无菌免疫”。由于包膜的构象复杂性和序列多样性,这一点很难做到。那些不能完全预防感染的抗体仍可减轻病毒感染负担,使强大的细胞免疫能够控制病毒血症、延缓疾病进展并防止病毒传播,同时还能为T细胞和B细胞反应提供帮助。采用包含复制载体和优化设计的包膜亚基的初免-加强策略,或许最有可能实现快速反应、强效、持久的免疫。